United States Pharmaceuticals Market Growth Insights & Trends 2025: Top 5 Pharma Companies - Pfizer Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, AstraZeneca

The Global Pharmaceuticals Market size reached US$ 1,740.44 Billion in 2024 from US$ 1,635.82 Billion in 2023 and is expected to reach US$ 3,178.63 Billion by 2033, growing at a CAGR of 7.0% during the forecast period 2025-2033

DataM Intelligence has published a new research report on "Pharmaceuticals Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/pharmaceutical-market?kb

According to WHO, by 2030, 1 in 6 people globally will be 60 or older, growing from 1 billion in 2020 to 1.4 billion. By 2050, this population will double to 2.1 billion. Longer life expectancy and increased medication needs among the elderly are driving pharmaceutical market growth.

The growing prevalence of chronic diseases and an ageing population are boosting pharmaceutical market growth. For example, the global diabetes crisis is increasing demand for insulin analogs and GLP-1 therapies from Novo Nordisk and Eli Lilly, while oncology sees rising demand for targeted drugs and immunotherapies amid increasing cancer cases.

Key Players:

Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., AbbVie Inc., AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, GSK plc, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Bayer AG, Merck KGaA, and Teva Pharmaceutical Industries Ltd., among others.

Industry Developments

In August 2025, Tonix Pharmaceuticals announced FDA approval of Tonmya (cyclobenzaprine HCl sublingual tablets) for adult fibromyalgia, a first-in-class, non-opioid, once-daily bedtime analgesic and the first new therapy for this condition in over 15 years.

Also in August 2025, Intas Pharmaceuticals launched HETRONIFLY (Serplulimab), the world's first PD-1 inhibitor for Extensive-Stage Small Cell Lung Cancer, in India following its European debut.

In July 2025, Sun Pharma launched LEQSELVI (deuruxolitinib) in the US for severe alopecia areata, showing rapid results with one-third of patients regaining nearly full scalp hair by Week 24 and some improvements as early as 8 weeks.

Growth Forecast Projected:

The Global Pharmaceuticals Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Pharmaceuticals Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pharmaceutical-market

Key Segments:

In 2024, branded drugs dominate the pharmaceuticals market, holding a 74.91% share.

Patent-protected branded drugs help companies recover R&D costs and earn high margins. Blockbusters like Keytruda (Merck) for oncology, Humira (AbbVie) for immunology, and Ozempic/Wegovy (Novo Nordisk) for diabetes and obesity generate tens of billions annually, significantly boosting company revenues.

By Type: Prescription Drugs | Over-the-Counter (OTC) Drugs

By Drug Type: Branded Drugs | Generic Drugs

By Therapeutic Area: Cardiovascular Diseases | Oncology | Neurology | Respiratory Diseases | Endocrine & Metabolic Diseases | Gastrointestinal Disorders | Musculoskeletal Disorders | Dermatology Disorders | Others

By Route of Administration: Oral | Topical | Parenteral | Inhalations | Others

By Distribution Channel: Hospital Pharmacies | Retail Pharmacies | Online Pharmacies

Regional Analysis for Market:

North America is projected to lead the global pharmaceuticals market, holding a 45.89% share in 2024.

North America leads the pharmaceuticals market, driven by high healthcare spending, advanced R&D, and major players like Pfizer, J&J, and Merck. The US, the largest global pharma market, fuels demand for branded and specialty drugs, with blockbusters like Keytruda, Humira, and Ozempic generating billions. Strong biotech clusters and a favorable FDA regulatory environment further support biologics and advanced therapies.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Pharmaceuticals producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Pharmaceuticals revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pharmaceutical-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.